Tuesday, November 5, 2024
Subscribe American Journal of Medicine Free Newsletter
Clinical ResearchOxygen Therapy in Patients with Acute Myocardial Infarction (video)

Oxygen Therapy in Patients with Acute Myocardial Infarction (video)

man holding chest and woman offering him water

 

Oxygen therapy is frequently used for patients with acute myocardial infarction. The aim of this study is to perform a systematic review and meta-analysis to compare the outcomes of oxygen therapy versus no oxygen therapy in post–acute myocardial infarction settings.

Methods

A systematic search of electronic databases was conducted for randomized studies, which reported cardiovascular events in oxygen versus no oxygen therapy. The evaluated outcomes were all-cause mortality, recurrent coronary events (ischemia or myocardial infarction), heart failure, and arrhythmias. Summary-adjusted risk ratios (RRs) were calculated by the random effects DerSimonian and Laird model. The risk of bias of the included studies was assessed by Cochrane scale.

Results

Our meta-analysis included a total of 7 studies with 3842 patients who received oxygen therapy and 3860 patients without oxygen therapy. Oxygen therapy did not decrease the risk of all-cause mortality (pooled RR, 0.99; 95% confidence interval [CI], 0.81-1.21; P = .43), recurrent ischemia or myocardial infarction (pooled RR, 1.19; 95% CI, 0.95-1.48; P = .75), heart failure (pooled RR, 0.94; 95% CI, 0.61-1.45; P = .348), and occurrence of arrhythmia events (pooled RR, 1.01; 95% CI, 0.85-1.2; P = .233) compared with the no oxygen arm.

Conclusions

This meta-analysis confirms the lack of benefit of routine oxygen therapy in patients with acute myocardial infarction with normal oxygen saturation levels.

Introduction

Ischemic heart disease is the most common cause of death worldwide.1 Furthermore, acute myocardial infarctions occur in approximately 790,000 Americans every year.2 Reperfusion therapy is the gold standard treatment strategy for patients who present with acute myocardial infarction.1 Other treatment therapies, such as routine oxygen therapy, have been evaluated to determine their impact on cardiovascular outcomes. Oxygen therapy in ischemic heart disease was first reported in 1900 and since that time has been incorporated in the usual care during acute treatment for patients with acute myocardial infarction.2 Previous animal and clinical studies hypothesized that supplemental oxygen up to even hyperoxic levels in patients with acute myocardial infarction would reduce myocardial injury by increasing oxygen delivery to ischemic myocardium.345 Yet, those studies were not randomized or blinded. Conversely, it has since been reported that hyperoxia may precipitate an increase in myocardial injury due to coronary vasoconstriction and oxidative stress.67 Yet the use of supplemental oxygen continued to be a routine practice in patients with cardiac disease. More important, no randomized, blinded, and controlled studies have shown an advantage in normoxemic patients, with surging evidence proving the conceivable adverse effects of hyperoxia in acute myocardial infarction.89 A Cochrane report from 2016 did not show any benefit to using oxygen in patients with acute myocardial infarction.8Additionally, a recent meta-analysis reviewed 5 randomized controlled trials and concluded that oxygen supplementation did not benefit patients with baseline normal peripheral oxygen saturations ≥90%.9

Most recently, a registry-based randomized clinical trial was performed to evaluate oxygen therapy on all-cause mortality at 1 year (The Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction),10 which showed that routine supplemental oxygen in patients without hypoxemia at baseline undergoing hospitalization for acute myocardial infarction did not have a reduced 1-year all-cause mortality. This study provides definitive evidence that supplemental oxygen is not beneficial in patients who have normal baseline oxygen saturations with acute myocardial infarction.11 In this context, we performed an updated meta-analysis with the most updated evidence to evaluate the efficacy of routine oxygen supplementation in patients with acute myocardial infarction.

Methods

Data Sources

An electronic search of the MEDLINE, Web of Science, and Cochrane Collaboration of Clinical Trials was performed from inception to November 2017 without language restriction, using the keywords “acute myocardial infarction,” “oxygen therapy,” “assessment,” and “outcomes,” as illustrated in Figure 1. Bibliographies of the included studies, relevant review articles, and meta-analyses were manually searched for any potential overlooked studies. The major cardiovascular conferences and proceedings, for example, American College of Cardiology and American Heart Association conferences, were screened for any abstracts addressing this topic.

You can read “Oxygen Therapy in Patients with Acute Myocardial Infarction: A Systematic Review and Meta-Analysis” by Abuzaid et al on our website.

This article originally appeared in the June 2018 issue  of The American Journal of Medicine.

Latest Posts

lupus

Sarcoidosis with Lupus Pernio in an Afro-Caribbean Man

A 54-year-old man of Afro-Caribbean ancestry presented with a 2-month history of nonproductive cough, 10-day history of constant subjective fevers, and a 1-day history...
Flue Vaccine

Flu Vaccination to Prevent Cardiovascular Mortality (video)

0
"Influenza can cause a significant burden on patients with coronary artery disease," write Barbetta et al in The American Journal of Medicine. For this...
varicella zoster

Varicella Zoster Virus-Induced Complete Heart Block

0
Complete heart block is usually caused by chronic myocardial ischemia and fibrosis but can also be induced by bacterial and viral infections. The varicella...
Racial justice in healthcare

Teaching Anti-Racism in the Clinical Environment

0
"Teaching Anti-Racism in the Clinical Environment: The Five-Minute Moment for Racial Justice in Healthcare" was originally published in the April 2023 issue of The...
Invisible hand of the market

The ‘Invisible Hand’ Doesn’t Work for Prescription Drugs

0
Pharmaceutical innovation has been responsible for many “miracles of modern medicine.” Reliance on the “invisible hand” of Adam Smith to allocate resources in the...
Joseph S. Alpert, MD

New Coronary Heart Disease Risk Factors

0
"New Coronary Heart Disease Risk Factors" by AJM Editor-in Chief Joseph S. Alpert, MD was originally published in the April 2023 issue of The...
Cardiovascular risk from noncardiac activities

Cardiac Risk Related to Noncardiac & Nonsurgical Activities

0
"Assessment of Cardiovascular Risk for Noncardiac and Nonsurgical Activities" was originally published in the April 2023 issue of The American Journal of Medicine. Cardiovascular risk...